ENDRA Life Sciences Inc. (NDRA) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does ENDRA Life Sciences Inc. Do?
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan. ENDRA Life Sciences Inc. (NDRA) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Francois Michelon and employs approximately 20 people. With a market capitalization of $5M, NDRA is one of the notable companies in the Healthcare sector.
ENDRA Life Sciences Inc. (NDRA) Stock Rating — Reduce (April 2026)
As of April 2026, ENDRA Life Sciences Inc. receives a Reduce rating with a composite score of 21.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.NDRA ranks #3,741 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ENDRA Life Sciences Inc. ranks #627 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
NDRA Stock Price and 52-Week Range
ENDRA Life Sciences Inc. (NDRA) currently trades at $4.94. The stock lost $0.37 (7.0%) in the most recent trading session. The 52-week high for NDRA is $11.96, which means the stock is currently trading -58.7% from its annual peak. The 52-week low is $2.90, putting the stock 70.3% above its annual trough. Recent trading volume was 21K shares, suggesting relatively thin trading activity.
Is NDRA Overvalued or Undervalued? — Valuation Analysis
ENDRA Life Sciences Inc. (NDRA) carries a value factor score of 10/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.93x, versus the sector average of 2.75x.
At current multiples, ENDRA Life Sciences Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
ENDRA Life Sciences Inc. Profitability — ROE, Margins, and Quality Score
ENDRA Life Sciences Inc. (NDRA) earns a quality factor score of 12/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -274.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -161.2% versus the sector average of -33.1%.
Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
NDRA Debt, Balance Sheet, and Financial Health
ENDRA Life Sciences Inc. has a debt-to-equity ratio of 71.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.29x, suggesting adequate working capital coverage. Total debt on the balance sheet is $396,537. Cash and equivalents stand at $794,036.
NDRA has a beta of 1.78, meaning it is more volatile than the broader market — a $10,000 investment in NDRA would be expected to move 77.8% more than the S&P 500 on any given day. The stability factor score for ENDRA Life Sciences Inc. is 12/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
ENDRA Life Sciences Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, ENDRA Life Sciences Inc. reported revenue of $0 and earnings per share (EPS) of $-8.93. Net income for the quarter was $-6M. Operating income came in at $-6M.
In FY 2025, ENDRA Life Sciences Inc. reported revenue of $0 and earnings per share (EPS) of $-8.93. Net income for the quarter was $-7M. Operating income came in at $-6M.
In Q3 2025, ENDRA Life Sciences Inc. reported revenue of $0 and earnings per share (EPS) of $-2.10. Net income for the quarter was $-2M. Operating income came in at $-1M.
In Q2 2025, ENDRA Life Sciences Inc. reported revenue of $0. Net income for the quarter was $-1M. Operating income came in at $-1M.
Over the past 8 quarters, ENDRA Life Sciences Inc. has experienced revenue contraction from $0 to $0. Investors analyzing NDRA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
NDRA Dividend Yield and Income Analysis
ENDRA Life Sciences Inc. (NDRA) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
NDRA Momentum and Technical Analysis Profile
ENDRA Life Sciences Inc. (NDRA) has a momentum factor score of 32/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 43/100 reflects moderate short selling activity.
NDRA vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, ENDRA Life Sciences Inc. (NDRA) ranks #627 out of 838 stocks based on the Blank Capital composite score. This places NDRA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing NDRA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NDRA vs S&P 500 (SPY) comparison to assess how ENDRA Life Sciences Inc. stacks up against the broader market across all factor dimensions.
NDRA Next Earnings Date
No upcoming earnings date has been announced for ENDRA Life Sciences Inc. (NDRA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy NDRA? — Investment Thesis Summary
The quantitative profile for ENDRA Life Sciences Inc. suggests caution. The quality score of 12/100 flags below-average profitability. The value score of 10/100 indicates premium valuation. Momentum is weak at 32/100, a headwind for near-term performance. High volatility (stability score 12/100) increases portfolio risk.
In summary, ENDRA Life Sciences Inc. (NDRA) earns a Reduce rating with a composite score of 21.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NDRA stock.
Related Resources for NDRA Investors
Explore more research and tools: NDRA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NDRA head-to-head with peers: NDRA vs AZN, NDRA vs SLGL, NDRA vs VMD.